Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
about
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisFingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceFingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerationsClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisOptimizing treatment success in multiple sclerosisThe Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsTumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatmentOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Sphingosine 1-phosphate receptor modulators in multiple sclerosisPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisFingolimod for the treatment of neurological diseases-state of play and future perspectivesLysophospholipid receptors in drug discovery.Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisFingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisInduced Stem Cells as a Novel Multiple Sclerosis TherapyNo quiet surrender: molecular guardians in multiple sclerosis brainRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisThe Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsAlemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.Therapeutic interference with leukocyte recirculation in multiple sclerosis.Newer multiple sclerosis drugs and disability scores-are key data analyses missing?Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological SocietyVaricella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protectionMeasuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study.No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.Oral disease-modifying therapies for multiple sclerosis.Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial
P2860
Q24187126-0034F6C5-42AC-4F8C-AFE4-9AC17AD1A89FQ26752466-542BDC9D-3E2E-4017-9001-5102C6EAEB79Q26765300-8B2CECCD-FE1E-45F7-B895-236803E71B36Q26771635-031ADB94-1D08-4E1C-8D9C-13C187D4BBAAQ26771968-CF9D38E2-C949-4CB1-B516-91C913BD4F1EQ26773978-C625D2E2-73FB-499E-8D37-A9A6052EDDF5Q26777329-81A2C752-795A-46B3-9053-259827179357Q26777684-F1DD1949-BDE1-4B65-83FC-C514FCBCBF70Q26777686-7453B728-927C-4447-BCD7-13E91F757EBFQ26798434-21637F1C-68F4-48DB-8C47-BDE0C58A8143Q26799440-72312BD1-45B5-4198-A55D-DAFB3E8947D4Q27000269-C86B34E6-7A10-48D2-B75D-EE292E672448Q27026175-EE3544D1-04D1-4AC7-B677-616689E3FA1CQ27692680-4ECECF66-F0FB-4237-BC91-2AEA19FE9A9BQ28066677-575EE462-80EF-4316-921F-39C86FB42737Q28068032-C86D92E9-2150-492F-A7B7-E7046FB85C7CQ28073377-41129A5E-736C-4D6F-8E5B-02DE3CDA08A9Q28081780-7CA71C1E-395B-4D52-8C53-0817C6F2BD6BQ28084633-BF281A8F-EED0-498F-B8C1-413C953ABEFCQ28087414-B7D1DECD-287B-4EF7-8806-918F6DE97607Q28601505-19C3C84A-680B-4BBE-89F6-0CC48ADB5E1AQ30458930-DC9106CA-0411-4752-B4C8-57C858D5E8CAQ30838717-37C1696D-3B39-4972-AD7D-6AD5D54BD3E6Q30884219-A99DCDEE-D8A2-4820-AF0C-8E3BD3776FF8Q30943783-CB2EFB02-18B7-4F77-855A-C55DA9D37297Q30965003-BC3EB922-12A8-4D28-BA93-906D6502DE3AQ31070072-2D0BA9B1-850B-4277-B44D-15A8C9A61B8BQ31117462-48796C84-45D5-49B6-9348-3806FE398B8CQ31123447-4C1A1E99-5A49-4254-A1B6-EF897E8FAA5DQ33562804-8E14ABA4-3B6D-4780-B8A0-ACCB6F598408Q33593619-CCC2C642-CE00-400E-80D6-3A72DA2E93D3Q33608864-606B5ABB-5297-4D9C-AD7D-06A87AFC3A4EQ33610149-7104FB80-6890-4EB9-B471-658ADFF8BBD2Q33642908-63EB6AC6-F4A4-475F-B83A-B07651BA18ABQ33697898-28910544-DCFC-4855-9705-AC06095C9916Q34577661-75CA60A7-4CB7-4AB3-B946-58CDFE236CF4Q34996562-2CA3435C-BD26-4FF0-8265-17D35EEC4BFBQ35030123-ACCB4295-40C2-45B0-A964-C63EC181AB01Q35116652-C281FE84-E15D-45C8-934C-6AD338270D9BQ35533579-08BDA465-995E-4ADA-8528-D91DB4875D4A
P2860
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety and efficacy of fingoli ...... ebo-controlled, phase 3 trial.
@ast
Safety and efficacy of fingoli ...... ebo-controlled, phase 3 trial.
@en
type
label
Safety and efficacy of fingoli ...... ebo-controlled, phase 3 trial.
@ast
Safety and efficacy of fingoli ...... ebo-controlled, phase 3 trial.
@en
prefLabel
Safety and efficacy of fingoli ...... ebo-controlled, phase 3 trial.
@ast
Safety and efficacy of fingoli ...... ebo-controlled, phase 3 trial.
@en
P2093
P50
P921
P1433
P1476
Safety and efficacy of fingoli ...... ebo-controlled, phase 3 trial.
@en
P2093
Anthony T Reder
Bingbing Li
Douglas Goodin
Douglas Jeffery
Ernst-Wilhelm Radue
Fred D Lublin
Kottil W Rammohan
Linda Cappiello
Mark A Agius
Philipp von Rosenstiel
P304
P356
10.1016/S1474-4422(14)70049-3
P577
2014-03-28T00:00:00Z